Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last781 to 800 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Intervention Arm vs Placebo Arm: Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy | 42 of 5,956 30 of 5,946 | 0.2 points -0.1 to 0.5 | 11,902 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Intervention Arm vs Placebo Arm: deaths from any cause | 9 of 5,943 12 of 5,936 | -0.1 points -0.2 to 0.1 | 11,879 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Intervention Arm vs Placebo Arm: serious adverse events | 832 of 5,943 857 of 5,936 | -0.4 points -1.7 to 0.8 | 11,879 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Intervention Arm vs Placebo Arm: Maternal Outcome 1 - Incidence of Vaginal Bleeding | 214 of 5,933 246 of 5,940 | -0.5 points -1.2 to 0.2 | 11,873 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Cases vs Controls: Number of Female Participants Aged 18-44 Using Oestrogen Contraceptive With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person | 31 of 4,917 34 of 6,925 | 0.1 points -0.1 to 0.4 | 11,842 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Intervention Arm vs Placebo Arm: Maternal Outcome 3 - Incidence of Postpartum Hemorrhage | 54 of 5,928 43 of 5,907 | 0.2 points -0.1 to 0.5 | 11,835 | NCT02409680 Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) |
| Pre-intervention vs Post-intervention: Cumulative Incidence of ART Initiation 14 Days After Clinical Eligibility in Treatment Eligible HIV-infected Patients | 2,585 of 7,066 3,753 of 4,747 | -42.5 points -44.1 to -40.8 | 11,813 | NCT01810289 The "START" (a Streamlined ART Initiation Strategy) Study |
| M-001 vs Saline: Number of Participants With Influenza-like Illness Symptoms | 1,231 of 5,864 1,266 of 5,905 | -0.4 points -1.9 to 1.0 | 11,769 | NCT03450915 A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine |
| M-001 vs Saline: Number of Participants With Culture-confirmed Influenza Incidence | 111 of 5,864 96 of 5,905 | 0.3 points -0.2 to 0.7 | 11,769 | NCT03450915 A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine |
| Anesthesia Control Tower Monitoring vs Standard of Care Arm: Antibiotic Redosing | 5,629 of 5,919 5,520 of 5,811 | 0.1 points -0.7 to 0.9 | 11,730 | NCT03923699 Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety |
| MF/F MDI BID vs MF MDI BID: deaths from any cause | 5 of 5,868 4 of 5,861 | 0.0 points -0.1 to 0.1 | 11,729 | NCT01471340 A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) |
| MF/F MDI BID vs MF MDI BID: serious adverse events | 136 of 5,868 137 of 5,861 | -0.0 points -0.6 to 0.5 | 11,729 | NCT01471340 A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) |
| Symbicort vs Budesonide: Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization) | 43 of 5,846 40 of 5,847 | 0.1 points -0.3 to 0.4 | 11,693 | NCT01444430 A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents |
| Symbicort vs Budesonide: Number of Participants Experiencing Discontinuation of Investigational Product Due to a Protocol Defined Asthma Exacerbation | 53 of 5,846 71 of 5,847 | -0.3 points -0.7 to 0.1 | 11,693 | NCT01444430 A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents |
| Symbicort vs Budesonide: Number of Participants Experiencing an Event Included in the Definition of Asthma Exacerbation | 539 of 5,846 633 of 5,847 | -1.6 points -2.7 to -0.5 | 11,693 | NCT01444430 A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents |
| Symbicort vs Budesonide: serious adverse events | 125 of 5,846 123 of 5,847 | 0.0 points -0.5 to 0.6 | 11,693 | NCT01444430 A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents |
| Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing at Least One Asthma Exacerbation | 480 of 5,834 597 of 5,845 | -2.0 points -3.0 to -0.9 | 11,679 | NCT01475721 SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. |
| Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation | 66 of 5,834 84 of 5,845 | -0.3 points -0.7 to 0.1 | 11,679 | NCT01475721 SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. |
| Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death) | 34 of 5,834 33 of 5,845 | 0.0 points -0.3 to 0.3 | 11,679 | NCT01475721 SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. |
| Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): serious adverse events | 134 of 5,834 125 of 5,845 | 0.2 points -0.4 to 0.7 | 11,679 | NCT01475721 SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=40
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02409680-e7b475cd",
"title": "Intervention Arm vs Placebo Arm: Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy",
"summary": "42 of 5956 against 30 of 5946; risk difference 0.2 points, 95% interval -0.1 to 0.5; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
"record": "/library/comparisons/NCT02409680-e7b475cd",
"nct_id": "NCT02409680",
"kind": "outcome",
"participants": 11902,
"risk_difference": {
"value": 0.002006303880661345,
"lower": -0.0008157526556614907,
"upper": 0.0048971215951896865
},
"group_1": "42 of 5,956",
"group_2": "30 of 5,946",
"difference": "0.2 points",
"interval": "-0.1 to 0.5",
"trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
},
{
"id": "NCT02409680-deaths",
"title": "Intervention Arm vs Placebo Arm: deaths from any cause",
"summary": "9 of 5943 against 12 of 5936; risk difference -0.1 points, 95% interval -0.2 to 0.1; NCT02409680, Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)",
"record": "/library/comparisons/NCT02409680-deaths",
"nct_id": "NCT02409680",
"kind": "deaths",
"participants": 11879,
"risk_difference": {
"value": -0.0005071766689207853,
"lower": -0.002177909665862456,
"upper": 0.0011056837322531042
},
"group_1": "9 of 5,943",
"group_2": "12 of 5,936",
"difference": "-0.1 points",
"interval": "-0.2 to 0.1",
"trial_title": "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=41",
"request_id": "w4Kl3vsnZ1ftX8ts"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant